Thailand Center of Excellence for Life Sciences

Automated Control Concepts Announces Rebranding to InflexionPoint

Retrieved on: 
Monday, September 18, 2023
Biotechnology, Health, Science, Research, Health Technology, ACC, Professional, Commitment, Service, History, Thailand Center of Excellence for Life Sciences, Critical infrastructure, Growth, R, Food, Renewable energy, Industrial design, Drink

Automated Control Concepts (ACC), a leading technology integration company providing high-quality control and information products, solutions, and services, in the Life Sciences, Food & Beverage & Critical Infrastructure business segments, is excited to announce a significant milestone in its 40-year journey.

Key Points: 
  • Automated Control Concepts (ACC), a leading technology integration company providing high-quality control and information products, solutions, and services, in the Life Sciences, Food & Beverage & Critical Infrastructure business segments, is excited to announce a significant milestone in its 40-year journey.
  • This rebranding initiative reflects our commitment to innovation, growth, and aligning our identity with our evolving mission and vision.
  • The new name, InflexionPoint, better captures the essence of who we are and where we're headed.
  • Same Dedicated Team: Our team of experts remains unchanged, and we are excited to continue serving our customers with the same level of expertise, professionalism, and dedication they have come to expect from Automated Control Concepts.

BIOTRONIK, Inc. Reaches Settlement with U.S. Department of Justice

Retrieved on: 
Friday, July 22, 2022
Time, Life, Consultant, Culture, Central District, Compliance, Office of Inspector General, U.S. Department of Health and Human Services, Meal, Travel, Office of Inspector General (United States), U.S. Department of Justice Office of Legislative Affairs, Multimedia, Thailand Center of Excellence for Life Sciences, Policy, Company, Human body, Heart, Texas Juvenile Justice Department, Justice, Growth, Justice minister, Privacy Office of the U.S. Department of Homeland Security, Pharmaceutical industry

The Company denies all allegations on behalf of itself and its highly regarded physician partners, and the parties have agreed that the settlement is not an admission of liability.

Key Points: 
  • The Company denies all allegations on behalf of itself and its highly regarded physician partners, and the parties have agreed that the settlement is not an admission of liability.
  • Under the terms of the settlement, the Company will pay the United States and certain states $12.95 million USD to avoid the time and expense of further proceedings.
  • "Our guiding principle, 'Excellence for Life,' is reflected in everything we do, including continuous enhancements to our culture of compliance.
  • BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years.

DGAP-News: Rentschler Biopharma adds highly experienced executive to team and provides update on progress at Rentschler ATMP

Retrieved on: 
Monday, June 13, 2022
Lonza, Company, Quality control, Rentschler, Business, Business development, Environment, Thailand Center of Excellence for Life Sciences, Therapy, Â, CDMO, ATMP, Patient, CGMP, Industry, History, General manager, Fine chemical, Pharmaceutical industry

Rob Panting, General Manager of Rentschler ATMP Ltd., said: It is my pleasure to welcome Kassim to our team.

Key Points: 
  • Rob Panting, General Manager of Rentschler ATMP Ltd., said: It is my pleasure to welcome Kassim to our team.
  • Rentschler ATMP continues that history, and it is gratifying to see the progress being made at our Stevenage site.
  • Rentschler Biopharma is a family-owned company with about 1,100 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA.
  • In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

Rentschler Biopharma adds highly experienced executive to team and provides update on progress at Rentschler ATMP

Retrieved on: 
Monday, June 13, 2022
Lonza, Company, Quality control, Rentschler, Business, Business development, Environment, Thailand Center of Excellence for Life Sciences, Therapy, Â, CDMO, GLOBE, ATMP, Patient, CGMP, Industry, History, General manager, Fine chemical, Pharmaceutical industry

Rob Panting, General Manager of Rentschler ATMP Ltd., said: It is my pleasure to welcome Kassim to our team.

Key Points: 
  • Rob Panting, General Manager of Rentschler ATMP Ltd., said: It is my pleasure to welcome Kassim to our team.
  • The company also today provided an update on the progress made at the ATMP facility since it was established last year.
  • Rentschler ATMP continues that history, and it is gratifying to see the progress being made at our Stevenage site.
  • In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

Leading medical device company to build Center for Excellence in Cellular Manufacturing in Greater Sacramento (Rancho Cordova)

Retrieved on: 
Monday, March 28, 2022
BLA, Cell, Life, Thailand Center of Excellence for Life Sciences, GSEC, The New England Journal of Medicine, CGT, Lymphatic system, First Northern Bank, Clinical trial, Growth, Cancer, Thermogenesis, Medicine, Food, Senior, University, Acute lymphoblastic leukemia, Center, Industry, Elijah Cummings Lower Drug Costs Now Act, San Francisco Bay, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Â, UC, GLOBE, San Francisco Bay Area, Efficiency, FDA, University of California, Davis, Blood, Patient, Partnership, City, Mobile phone, Pharmaceutical industry, Management, Sacramento metropolitan area, Excellence

The CAR-T cell therapy, along with other cell-based therapies, will now be the focus at the Center for Excellence.

Key Points: 
  • The CAR-T cell therapy, along with other cell-based therapies, will now be the focus at the Center for Excellence.
  • ThermoGenesis new facility in Greater Sacramento will help alleviate some of these barriers, increasing both production and accessibility.
  • The City of Rancho Cordova is proud to welcome ThermoGenesis new Center for Excellence in Cellular Manufacturing to our community, said City Manager Cyrus Abhar.
  • Thermogenesis is the latest among a string of cell and gene therapy companies exploring expansions and relocations into the Greater Sacramento region.

AGC Biologics Receives Transatlantic Award for Investments in Milan Biopharmaceutical Industry

Retrieved on: 
Monday, December 20, 2021
American Chamber of Commerce in the People's Republic of China, RNA, RNA transfection, Professional, Economic development, KKR, DiaSorin, Growth, American, Center, Plasmid, Apple, Chamber of commerce, Degenerative disease, List of diplomatic missions of the United States, Commerce, Specialization, Molecular medicine, Ambassador, Thailand Center of Excellence for Life Sciences, Economy, CDMO, DNA, MolMed, Investment, Studio, Coca-Cola, GLOBE, AGC, GMP, Center of excellence, Contract, Fine chemical, Pharmaceutical industry

Milan, Dec. 20, 2021 (GLOBE NEWSWIRE) -- AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it has won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham).

Key Points: 
  • Milan, Dec. 20, 2021 (GLOBE NEWSWIRE) -- AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it has won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham).
  • Luca Alberici, AGC Biologics General Manager and Site Head of the Milan facility, received the award on behalf of the company during the XV Transatlantic Award Gala Dinner , held on December 2 at Studio 90 East End Studios in Milan.
  • I am happy and honored to receive this award on behalf of AGC Biologics.
  • This is an important award that showcases the investments our company has made in our Milan site, as well as the growing biopharmaceutical industry in our region, said AGC Biologics Milan General Manager and Site Head, Luca Alberici.

MilliporeSigma Announces Completion of New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

Retrieved on: 
Tuesday, October 12, 2021
Entrepreneurship, Merck Group, Electronics, Health, Food and Drug Administration, Solution, Food, List of life sciences, Multimedia, Merck, Federal Executive Boards, LinkedIn, Growth, Körber Process Solutions, Investment, Board of directors, Adoption, Thailand Center of Excellence for Life Sciences, CDMO, CEO, Degenerative disease, Intelligence, Science, Patient, Merck Millipore, Merck Serono, Fine chemical, Pharmaceutical industry, Vaccine, Mail

This new $110 million, 140,000-square footfacility will more than double the Life Science business sector's existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy, in a marketexpected to grow to $10 billion by 2026.

Key Points: 
  • This new $110 million, 140,000-square footfacility will more than double the Life Science business sector's existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy, in a marketexpected to grow to $10 billion by 2026.
  • "As a leader in viral vector manufacturing, this increase in capacity and scale is the next step in enabling our customers to bring new curative treatments to market."
  • The new facility leverages cutting-edge suspension technology to enable scalable and cost-effective manufacturing.
  • "We are continuing to invest in solving cell and gene therapy challenges in development and manufacturing, working alongside drug developers to industrialize, scale and accelerate the path to deliver therapies to patients," Heinzel added.

Thailand to develop strategic initiatives in the biomedical, life science and medical device industries in collaboration with PhenoMx, Inc. a US healthtech company

Retrieved on: 
Monday, October 28, 2019
Thailand Center of Excellence for Life Sciences

LONDON , Oct. 28, 2019 (GLOBE NEWSWIRE) -- The Thailand Center of Excellence for Life Sciences (TCELS), a public organisation, and PhenoMx, Inc. , a US-based health technology company, announced the execution of a Memorandum of Understanding (MOU) to develop strategic initiatives for Thailand in the biomedical, life science and medical device industries.

Key Points: 
  • LONDON , Oct. 28, 2019 (GLOBE NEWSWIRE) -- The Thailand Center of Excellence for Life Sciences (TCELS), a public organisation, and PhenoMx, Inc. , a US-based health technology company, announced the execution of a Memorandum of Understanding (MOU) to develop strategic initiatives for Thailand in the biomedical, life science and medical device industries.
  • The collaboration involves matching companies and research institutes in Thailand and the US to encourage more interaction between different stakeholders in the industry, as well as fostering innovation and commercialisation in the biomedical, life science and medical device industries.
  • TCELS has taken part in value chain development of the life sciences industry, supporting entrepreneurs in Thailand and research from upstream to downstream to meet national demand.
  • It is also driven by medical tourism, which is growing by 10 percent a year, and the government is reinforcing its policy to make Thailand the medical hub of the region.